Valion Bio, Inc. (VBIO): Nasdaq/NYSE listing notice — Tivic Health receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Valion Bio, Inc.

Received Nasdaq notification on March 19, 2026 for bid price below $1.00 for 30 consecutive business days.
Compliance period ends September 15, 2026; must have closing bid ≥$1.00 for 10 consecutive days.
If not compliant by Sept 15, may qualify for second 180-day period if other listing standards met.
Stock remains listed on Nasdaq Capital Market with no immediate effect on trading.
Company will monitor and consider available options to resolve the deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Valion Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

March 19, 2026, Tivic Health Systems, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification has no immediate effect

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-002064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.